Q2 2026 saw 3% sales growth driven by key brands, but net income fell 19% due to higher taxes and interest expense. Major acquisitions increased debt and goodwill, while strong pipeline progress and new product approvals support future growth.Original document: Novartis AG [NOVN] Interim report — J…
Q2 2026 saw 3% sales growth driven by key brands, but net income fell 19% due to higher taxes and interest expense. Major acquisitions increased debt and goodwill, while strong pipeline progress and new product approvals support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.